Navigation Links
Flagship Biosciences Introduces a New Technique for Measuring Fibrosis in Nonalcoholic Steatohepatitis
Date:6/24/2013

Portland, OR (PRWEB) June 24, 2013

Nonalcoholic steatohepatisis or NASH is a common, often "silent" chronic liver disease, occurring in people who drink little or no alcohol. Emerging antifibrotic therapies are aimed at inhibiting the accumulation of fibrogenic cells and/or preventing the deposition of extracellular matrix proteins.

Fibrosis generally occurs at a low area percentage in tissue, and manual subjective evaluation cannot accurately discern discrete changes at low levels. To address this obstacle, Flagship's quantitative Tissue Image Analysis (tIA) method has been used to determine precise percentages of induced fibrosis in various experimental animal models. Results allowed discrimination of induction and therapy-related reductions in collagen levels at less than 5% increments, and these changes can only be measured accurately with computer-assisted pathology.  Data from tIA can be combined with histomorphologic and molecular data to allow greater utilization of animal tissue in antifibrotic drug development.

This quantitative approach of measuring fibrosis is being applied to different liver fibrosis-inducing models and in different species. This same approach has also been applied to measure fibrosis in cardiac and renal tissues and is being investigated for use in pulmonary fibrosis animal models.

Flagship's approach combines the expert knowledge of experienced scientists with innovations in digital pathology, leading to greater data accuracy and more efficient utilization of resources in drug development.

Flagship develops new tissue analysis endpoints for use in both research and CLIA clinical trials as part of their histology services.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10852679.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Clinovo, Leading CRO in the Bay Area, Endorsed by Medical Device Company for Their Flagship System: Clincapture
2. BioXcel Launches Its Flagship Product, PharmGPS™
3. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
4. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
5. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
6. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
7. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
8. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
9. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
10. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
11. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... At its national board meeting in ... Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology ... in ARCS Alumni Hall of Fame . ASTER Labs is a technology ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit ... 7th and 8th June 2018 in San Francisco, CA. The Summit brings together current ... several distinguished CEOs, board directors and government officials from around the world to address ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
Breaking Biology Technology:
(Date:8/23/2017)... , Aug. 23, 2017  The general public,s help is being enlisted ... bacteria that live in and on the human body –and are believed ... The Microbiome Immunity ... human microbiome, starting with the gut. The project's goal is to help ... credit: IBM ...
(Date:6/14/2017)...  IBM (NYSE: IBM ) is introducing several innovative ... to developing collaboration between startups and global businesses, taking place ... the event, nine startups will showcase the solutions they have ... France is one ... a 30 percent increase in the number of startups created ...
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
Breaking Biology News(10 mins):